Khiron Life Sciences (STU:4KH) PB Ratio: 0.23 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Khiron Life Sciences PB Ratio?

Khiron Life Sciences STU:4KH PB Ratio is 0.23 as of Aug. 01, 2026.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-01), Khiron Life Sciences's share price is €0.0216. Khiron Life Sciences's Book Value per Share for the quarter that ended in Sep. 2022 was €0.10. Hence, Khiron Life Sciences's PB Ratio of today is 0.23.

The historical rank and industry rank for Khiron Life Sciences's PB Ratio or its related term are showing as below:

STU:4KH's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.88
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio

Khiron Life Sciences  (STU:4KH) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Khiron Life Sciences PB Ratio Related Terms

Khiron Life Sciences PB Ratio Historical Data

* Premium members only.

The historical data trend for Khiron Life Sciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Khiron Life Sciences PB Ratio Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.94 1.63 0.81 1.10

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 1.10 1.51 0.78 0.67

STU:4KH vs ZTS, CTLT, VTRS: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Khiron Life Sciences PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's PB Ratio falls into.


Khiron Life Sciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Khiron Life Sciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2022)
=0.0216/0.095
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PB Ratio=Market Cap /(Total Stockholders Equity-Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 0.23 mean?
Khiron Life Sciences (STU:4KH) has a PB Ratio of 0.23 as of Aug. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Khiron Life Sciences and its competitors.
Is Khiron Life Sciences' PB Ratio too high?
Khiron Life Sciences' current PB Ratio is 0.23. The Drug Manufacturers industry median PB Ratio is 1.88. Khiron Life Sciences' value of 0.23 is 87.8% below this industry median.
How does Khiron Life Sciences' PB Ratio compare to ZTS and CTLT?
Khiron Life Sciences' PB Ratio of 0.23 can be compared against companies in the Drug Manufacturers industry. The industry median PB Ratio is 1.88. Khiron Life Sciences' value of 0.23 is 87.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Khiron Life Sciences's current PB Ratio of 0.23 is 87.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Khiron Life Sciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Khiron Life Sciences's current PB Ratio is 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Khiron Life Sciences stock overvalued right now?
Khiron Life Sciences (STU:4KH) has a current PB Ratio of 0.23. The current PB Ratio is 0.23 and 87.8% below the Drug Manufacturers industry median of 1.88. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Khiron Life Sciences (STU:4KH), the current PB Ratio is 0.23 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Khiron Life Sciences Business Description

Address 2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.